Morphic therapeutic to host webcast to present emerald-1 full data set

Waltham, mass., oct. 09, 2023 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label emerald-1 phase 2a study of morf-057 in adults with moderate to severe ulcerative colitis. the positive topline results from emerald-1 were reported in april of this year and the full data set will be presented at the upcoming ueg week 2023.
MORF Ratings Summary
MORF Quant Ranking